中国学者近期发表的论文
Letter: Improving the Interpretability and Portability of Tumour Burden Score-Based Prediction of Extrahepatic Progression After Transarterial Chemoembolization (TACE
Journal: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2026; Vol. 63, Issue 9, pp. 1323-1324. DOI: 10.1111/apt.70562
Letter: Association of Diabetes Mellitus With Post-TIPS Hepatic Encephalopathy in a Predominantly Viral Cirrhosis Cohor
Journal: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2026; Vol. 63, Issue 7, pp. 1073-1074. DOI: 10.1111/apt.70520
Letter: Are All Extra-Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story
Journal: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2026; Vol. , Issue , pp. -. DOI: 10.1111/apt.70650
Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2311
Journal: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2026; Vol. , Issue , pp. -. DOI: 10.1111/apt.70612
Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangiti
Journal: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2026; Vol. , Issue , pp. -. DOI: 10.1111/apt.70664
Letter: Double PBC-Related Autoantibody Positivity-How Essential Is It for Diagnosis? Authors' Repl
Journal: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2026; Vol. , Issue , pp. -. DOI: 10.1111/apt.70685
Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Repl
Journal: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2026; Vol. , Issue , pp. -. DOI: 10.1111/apt.70684
Letter: Beyond Survival Benefit in CHANCE2311-Important Considerations in the Interpretation of TACE Combined With Immunotherapy in Advanced HC
Journal: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2026; Vol. , Issue , pp. -. DOI: 10.1111/apt.70686
Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Diseas
Journal: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2026; Vol. , Issue , pp. -. DOI: 10.1111/apt.70700
Letter: Beyond Feasibility: The Need for Longer Duration and Composite NIT Endpoints in Biopsy-Free MASH Trial
Journal: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2026; Vol. , Issue , pp. -. DOI: 10.1111/apt.70701
高引用文章
Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis
引用次数:40
Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions
引用次数:29
Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome
引用次数:27
Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease
引用次数:25
Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection
引用次数:23
Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation
引用次数:20
Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease
引用次数:19
The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity
引用次数:18
Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years
引用次数:17
One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing
引用次数:17